Scilex Holding

Scilex Holding is a revenue-generating biopharma company singularly focused on building a leading franchise in non-opioid pain management. Its strategy combines the commercialization of three approved products—ZTlido®, Elyxyb®, and Gloperba®—with the development of a late-stage pipeline, headlined by SEMDEXA™ (SP-102) for sciatica, which has completed a successful Phase 3 trial. The company aims to address the opioid crisis by providing healthcare providers and patients with effective, non-addictive therapeutic options across a spectrum of pain indications, from neuropathic pain to migraine and gout prophylaxis.

A product-focused platform centered on advanced formulation science and targeted drug delivery systems, including novel topical adhesives, viscous gel injectables, and modified-release oral formulations to enhance the efficacy and safety of known therapeutic agents.